Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases

M Çakan, ŞG Karadağ, NA Ayaz - The Turkish Journal of Pediatrics, 2020 - turkjpediatr.org
anakinra before canakinumab in 14 of 19 crFMF patients with a mean duration of 6 months
and have seen that anakinraEfficacy of antiIL-1 treatment in familial Mediterranean fever: a …

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)

G El Hasbani, A Jawad, I Uthman - Orphanet journal of rare diseases, 2019 - Springer
… Shortly after that, the efficacy of Anakinra in the treatment of a colchicine resistant 68 year
old woman homozygous for the M694 V mutation of the MEFV gene [43] and a 15 year-old …

Effectiveness of canakinumab in colchicine-and anakinra-resistant or-intolerant adult familial Mediterranean fever patients: a single-center real-life study

H Babaoglu, O Varan, H Kucuk, N Atas… - JCR: Journal of …, 2020 - journals.lww.com
… in the prevention of attacks in patients with colchicine-resistant FMF (crFMF) or colchicine-intolerant
FMF. Interleukin 1 antagonists, anakinra, canakinumab, and rilonacept, have been …

The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever: a systematic review of the literature

M Kacar, S Savic, JCH van der Hilst - Journal of inflammation …, 2020 - Taylor & Francis
… in colchicine-resistant FMF (crFMF) patients since the beginning of this century. Citation8
Anakinra, a … effective and safe in patients with colchicine-resistant or colchicine-intolerant FMF. …

The remarkable characteristics of the children with colchicine-resistant familial Mediterranean fever in Turkey

N Sahin, S Ozdemir Cicek, A Pac Kisaarslan… - Modern …, 2022 - academic.oup.com
… achieved good outcomes about effectiveness and safety [20]. Anakinra and canakinumab
are … Anakinra and canakinumab succeeded in complete remission in more than two-third of …

Conventional and novel therapeutic options in children with familial Mediterranean fever: A rare autoinflammatory disease

D Poddighe, M Romano… - British journal of …, 2022 - Wiley Online Library
… more frequent in the colchicine-resistant group (97% vs 68% in … of CNK for FMF adults,
adolescents and children aged 2 years and … started etanercept (0.8 mg/kg/week). The therapy with …

… treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine” of the Society for Pediatric and Adolescent …

T Sahr, U Kiltz, C Weseloh, T Kallinich… - Zeitschrift für …, 2020 - Springer
Familial Mediterranean fever (FMF) is a genetic disease of childhood and adulthood
which is relatively rare in Germany. It is characterized by recurrent febrile attacks, peritonitis, …

Evidence-based treatment recommendations for familial Mediterranean fever: a joint statement by the Society for Pediatric and Adolescent Rheumatology and the …

T Kallinich, N Blank, T Braun, E Feist, U Kiltz… - Zeitschrift für …, 2019 - Springer
Familial Mediterranean fever (FMF) in Germany is a rare, genetically linked disease of
childhood and adolescence, which is characterized by recurrent febrile episodes and clinical …

The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever

SO Cebeci, M Yildiz, A Gunalp, MN Cebi… - Rheumatology …, 2024 - Springer
efficacy of anti-IL-1 agents in colchicine-resistant pediatric FMF patients, the experience of
using on-demand anakinra … Although a single-dose subcutaneous anakinra administration is …

Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature …

S Eren Akarcan, S Dogantan, N Edeer Karaca… - Rheumatology …, 2020 - Springer
… and safety of canakinumab in children and adolescents-young adults [11, 15]. In both studies,
… of colchicine-resistant patients, its efficacy for clinical findings and its cost effectiveness will …